Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors

Breast Cancer Research and Treatment

Volumn 142, Issue 3, 2013, Pages 629-636

  Kaplan, Henry G ^a   Malmgren, Judith A ^b,c   Li, Christopher I ^c,d   Calip, Gregory S ^c,d  

^a SWEDISH MEDICAL CENTER   (United States)

^b HealthStat Consulting Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute myeloid leukemia; Breast cancer; Myelodysplastic syndrome; Myeloid leukemia; Risk analysis; Survivorship

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RISK; SEER PROGRAM; SURVIVORS; YOUNG ADULT;

EID: 84890253761     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2773-x     Document Type: Article

References (39)

1. Early Breast Cancer Trialists' Collaborative Group (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analysis of long term outcome among 100,000 women in 123 randomized trials. Lancet 379(9814):432-444
2. Larson RA (2009) Therapy-related myeloid neoplasms. Haematologica 94(4):454-459
3. Curtis R, Boice J, Stovall M, et al. (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751
4. Renella R, Verkooijen HM, Fioretta G, et al. (2006) Increased risk of acute myeloid leukaemia after treatment for breast cancer. The Breast 15:614-619
5. Crump M, Dongsheeng T, Shepherd L, Levine M, Pritchard K (2003) Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clinic Oncol 21:3066-3071
6. Praga C, Bergh J, Bliss J, et al. (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23:4179-4191
7. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ (2009) Therapy related acute myeloid leukemia in breast cancer survivors, a population based study. Breast Cancer Res Treat 118:593-598. doi: 10.1007/s10549-009-0376-3
8. Kaplan HG, Malmgren JA, De Roos AJ (2013) Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study. Breast Cancer Res Treat 137(3):863-867. doi: 10.1007/s10549-012-2386-9
9. Kaplan HG, Malmgren JA, Atwood MK (2011) Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC Cancer 11:260. doi: 10.1186/1471-2407-11-260
10. De Roos AJ, Deeg HJ, Davis S (2007) A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 18:1199-1208
11. NCCN guidelines version 1.2013 © National Comprehensive Cancer Network, Inc. 2012. Accessed 18 February 2013
12. Narod SA (2012) Breast cancer in young women. Nat Rev Clin Oncol 9:460-470. doi: 10.1038/nrclinonc.2012.102
13. Kaplan HG, Malmgren JA, Atwood MK (2013) Adjuvant chemotherapy and differential invasive breast cancer specific survival in elderly women. J Geriatr Oncol 4(2):148-156. doi: 10.1016/j.jgo.2012.12.007
14. http://seer.cancer.gov/about/overview.html. Accessed 21 February 2013
15. SEER (2012). Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEERStat Database: Incidence - SEER 18 Regs Research Data, Nov 2011 Sub (2000-2009) - linked to county attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the Nov 2011 submission
16. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012. Accessed 11 Dec 2012
17. Fritz A, Percy C, Jack A, ShanmurgaratnamK, Sobin L, Parkin D, Whelan S, eds. International classification of diseases for oncology. World Health Organization, Geneva. http://www.who.int/classifications/icd/en/. Accessed 21 Feb 2013
18. Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version <7.1.0>. http://seer.cancer. gov/seerstat/software/. Accessed on 21 Feb 2013
19. Malin JL, Kahn KL, Adams J, et al. (2002) Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 94(11):835-844
20. Jagsi R, Abrahmse P, Hawley ST, et al. (2012) Under ascertainment of radiotherapy receipt in surveillance, epidemiology, and end results registry data. Cancer 118:333-341
21. National comprehensive cancer network clinical practice guidelines in oncology: breast cancer (2013). Version 1.2013, 2/1/2013 © National Comprehensive Cancer Network, Inc.
22. Psaty BM, Koepsell TD, Lin D, et al. (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749-754
23. McCullagh P, Nelder JA (1989) Generalized linear models. Chapman and Hall, London
24. Godley LA, Larson RA (2008) Therapy-related myeloid leukemia. Semin Oncol 35(4):418-429. doi: 10.1053/j.seminoncol.2008.04.012
25. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102:43-52. doi: 10.1182/blood-2002-11-3343
26. Karp JE, Blackford A, Visvanathan K, et al. (2012) Myelodysplastic syndrome and/or acute myelogenous leukemia after a breast cancer diagnosis: The National Comprehensive Cancer Network experience. Cancer Res 72((24):S3-S5
27. Smith RE, Bryant J, DeCillis A, Anderson S (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 21:1195-1204
28. Hershman D, Neugut AI, Jacobsen JS, et al. (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Nat Cancer Inst 99:196-205
29. Shulman LN, Cirrincione CT, Berry DA, et al. (2012) Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 30:4071-4076
30. Moebus V, Jackish C, Lueck H-J, et al. (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874-2880
31. Swain SM, Tang G, Geyer CE, et al. (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197-3204. doi: 10.1200/JCO.2012.48.1275
32. Koontz MZ, Horning SJ, Balise R, et al. (2013) Risk of therapy-related secondary leukemia in Hodgkin Lymphoma: The Stanford University Experience over three generations of clinical trials. J Clin Oncol 31:592-596
33. Wakeford R (2004) The cancer epidemiology of radiation. Oncogene 23(38):6404-6428
34. Mauch PM, Kalish LA, Marcus KC, et al. (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 87(9):3625-3632
35. Swerdlow AJ, Barber JA, Vaughan Hudson G, et al. (2000) Risk of second malignancy after Hodgkin's disease in a Collaborative British Cohort: the relation to age at treatment. J Clin Oncol 18(3):498-509
36. Johnson RH, Chien FL (2009) Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800-805
37. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36(3):237-249
38. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4(11):e7695
39. Morton LM, Dores GM, Tucker MA, et al. (2013) Evolving risk of therapy-related acute myeloid leukemia following chemotherapy among adults in the United States, 1975-2008. Blood 121(15):2996-3004. doi: 10.1182/blood-2012- 08-448068